UBS Group’s Tenaya Therapeutics TNYA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$460K Buy
665,180
+85,579
+15% +$63.2K ﹤0.01% 6140
2025
Q4
$413K Buy
579,601
+382,874
+195% +$521K ﹤0.01% 6194
2025
Q3
$319K Buy
196,727
+76,551
+64% +$77.1K ﹤0.01% 6395
2025
Q2
$73.4K Sell
120,176
-134,568
-53% -$68.5K ﹤0.01% 7476
2025
Q1
$145K Sell
254,744
-223,764
-47% -$221K ﹤0.01% 6767
2024
Q4
$684K Buy
478,508
+452,370
+1,731% +$1.01M ﹤0.01% 5625
2024
Q3
$50.4K Buy
26,138
+9,293
+55% +$26.2K ﹤0.01% 6815
2024
Q2
$52.2K Sell
16,845
-93,331
-85% -$385K ﹤0.01% 6655
2024
Q1
$576K Buy
110,176
+65,162
+145% +$312K ﹤0.01% 5091
2023
Q4
$146K Buy
45,014
+19,530
+77% +$42.2K ﹤0.01% 5964
2023
Q3
$65K Sell
25,484
-837
-3% -$3.5K ﹤0.01% 6121
2023
Q2
$155K Buy
26,321
+11,592
+79% +$67.4K ﹤0.01% 5659
2023
Q1
$42K Buy
14,729
+2,669
+22% +$7.5K ﹤0.01% 6576
2022
Q4
$24.2K Buy
+12,060
New +$29.4K ﹤0.01% 7455
2022
Q3
Sell
-261
Closed -$1K 10931
2022
Q2
$1K Sell
261
-106
-29% -$858 ﹤0.01% 9967
2022
Q1
$4K Sell
367
-2,923
-89% -$35.4K ﹤0.01% 9323
2021
Q4
$62K Buy
3,290
+2,915
+777% +$63.5K ﹤0.01% 6728
2021
Q3
$8K Buy
+375
New +$8.06K ﹤0.01% 8228

Other funds holding TNYA

UBS Group's TNYA Position: Q1 2026 in Review

UBS Group increased its Tenaya Therapeutics (TNYA) stake by 15% in Q1 2026, buying an estimated $63.2K and bringing the position to 665,180 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #6140.

UBS Group first reported a position in TNYA in Q3 2021 and has held it in 18 quarters since. The position peaked at $684K in Q4 2024. 103 funds tracked by Wall St. Rank hold TNYA as of Q1 2026.

  • UBS Group held 665,180 shares of Tenaya Therapeutics worth $460K as of Q1 2026.
  • UBS Group bought 85,579 Tenaya Therapeutics shares in Q1 2026, an estimated $63.2K.
  • Tenaya Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6140 holding.
  • UBS Group first reported a position in Tenaya Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • UBS Group's Tenaya Therapeutics position peaked at $684K in Q4 2024.
  • 103 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.